BRISTOL-MYERS SQUIBB CO (BMY) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:BMY - US1101221083 - Common Stock
BMY Key Statistics, Chart & Performance
The current stock price of BMY is 55.86 USD. In the past month the price increased by 9.08%. In the past year, price increased by 0.05%.
BMY Latest News, Press Relases and Analysis
BMY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 17.28 | 4.07B |
Related stock screener links
About BMY
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016 US
CEO: Giovanni Caforio
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / BMY FAQ
What does BRISTOL-MYERS SQUIBB CO do?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the current price of BMY stock?
The current stock price of BMY is 55.86 USD. The price decreased by -0.07% in the last trading session.
Does BMY stock pay dividends?
BRISTOL-MYERS SQUIBB CO (BMY) has a dividend yield of 4.51%. The yearly dividend amount is currently 2.42.
What is the ChartMill technical and fundamental rating of BMY stock?
BMY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (BMY) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy BMY stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BMY.
What is the market capitalization of BMY stock?
BRISTOL-MYERS SQUIBB CO (BMY) has a market capitalization of 113.72B USD. This makes BMY a Large Cap stock.
BMY Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BMY. When comparing the yearly performance of all stocks, BMY turns out to be only a medium performer in the overall market: it outperformed 69.96% of all stocks.
BMY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BMY. BMY has an excellent profitability rating, but there are some minor concerns on its financial health.
BMY Financial Highlights
Over the last trailing twelve months BMY reported a non-GAAP Earnings per Share(EPS) of 6.56. The EPS increased by 460.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
BMY Forecast & Estimates
34 analysts have analysed BMY and the average price target is 55.28 USD. This implies a price decrease of -1.04% is expected in the next year compared to the current price of 55.86.
For the next year, analysts expect an EPS growth of 478.44% and a revenue growth 0.22% for BMY